1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Xiamen Kingdomway Group Company

Xiamen Kingdomway Group Company

002626.SZ
Xiamen Kingdomway Group CompanyCN flagShenzhen Stock Exchange
13.87
CNY
-0.37
- -
8.46BMarket Cap
Xiamen Kingdomway Group Company
002626.SZ
(Shenzhen Stock Exchange)

Recent

price

13.87

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.25
1.27
1.16
1.15
1.47
2.14
2.83
3.39
4.64
5.17
5.74
5.91
4.91
5.05
5.31
5.54
5.66
Revenue per Share
0.33
0.29
0.17
0.18
0.34
0.2
0.51
0.77
1.11
0.73
1.57
1.29
0.42
0.45
0.56
0.56
0.75
Basic EPS, GAAP
0.19
-0.01
0.03
0.11
0.13
-1.14
0.6
0.66
1.3
1.2
1.18
0.82
0.87
0.66
0.26
0.54
-0.58
Free Cash Flow per Basic Share
0.04
0.09
0.1
0.09
0.15
0.18
0.08
0.23
0.44
0.9
0.65
0.67
0.66
0.26
0.24
0.45
0.45
Dividend per Share
0.73
0.94
0.96
1.03
1.41
1.98
2
2.42
3.03
2.81
3.73
4.42
4.23
4.47
4.86
5.05
4.88
Book Value per Share
0.81
2.64
2.15
2.23
2.45
1.22
2.2
2.69
2.84
3.32
4.08
5.11
4.7
5.11
5.62
6.18
5.79
Tangible Book Value per Share
429
455
581
584
572
563
588
616
619
617
611
612
613
615
611
607
609
Basic Weighted Avg Shares
536
578
676
670
838
1,204
1,663
2,085
2,873
3,192
3,504
3,616
3,009
3,103
3,240
3,365
3,445
Sales/Revenue/Turnover
32.43
28.54
16
16.01
24.43
12.11
21.31
29.41
33.77
28.3
34.42
30.03
16.02
11.53
14.87
15.82
17.38
Operating Margin (%)
25
27
34
38
50
72
88
83
98
120
112
179
207
209
205
209
- -
Depreciation Expense
142
132
102
102
195
113
300
474
687
451
959
789
257
277
342
340
459
Net Income, GAAP
15.14
16.52
13.72
14.07
15.78
16.13
17.36
17.62
17.73
25.82
16.78
16.04
21.11
17.46
21.83
15.13
19.25
Effective Tax Rate (%)
26.39
22.86
15.04
15.24
23.21
9.35
18.03
22.74
23.92
14.12
27.37
21.81
8.55
8.92
10.55
10.1
13.33
Profit Margin (%)
103
903
835
773
863
316
1,042
1,256
1,060
1,157
973
1,469
1,089
1,381
1,446
2,725
1,556
Working Capital
32
52
- -
- -
- -
289
380
334
734
776
681
896
467
653
715
1,693
819
LT Debt
369
1,221
1,269
1,317
1,421
1,541
2,180
2,491
3,021
2,955
3,492
4,027
3,665
3,936
4,318
4,496
4,375
Total Equity
34.7
15.33
7.15
7.13
12.58
6.15
10.77
17.06
22.13
15.97
22.22
18.27
7.68
6.17
7.15
7.12
8.52
Return on Invested Capital (%)
39.34
28.5
18.98
17.71
26.79
8.26
15.51
25.79
28.47
16.05
29.83
21.92
7.9
8.47
8.47
8.21
10.81
Return on Capital (%)
56
35.75
20.72
17.66
27.7
11.74
26.18
35.53
40.8
24.95
47.78
31.67
9.72
10.37
11.97
11.27
16.04
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
672
791
1,024
LT Borrowings
538
681
627
LT Finance Leases
177
168
192
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
610
610
610
Market Capitalization
8,908
9,052
12,454

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,667
3,035
3,064
Cash, Cash Equivalents & STI
1,343
1,626
1,718
Accounts Receivable, Net
408
459
450
Inventories
814
866
811
Total Current Liabilities
1,221
1,304
1,508
Payables & Accruals
- -
- -
- -
ST Debt
672
791
1,024
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.05%
5.51%
4.11%
Free Cash Flow
-5.3%
-0.12%
108.54%
Net Income, GAAP
29.31%
-10.93%
-0.61%
Sales/Revenue/Turnover
12%
-0.44%
3.87%
Total Cash Common Dividend
32.87%
4.31%
88.4%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
743
780
819
897
3,240
2025
827
901
761
- -
3,365
2026
813
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
- -
- -
- -
0.56
2025
0.2
- -
- -
- -
0.56
2026
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.24
2025
0.02
- -
- -
- -
0.45
2026
0.01
- -
- -
- -
- -
Similar Companies
Natco Pharma Limited (NATCOPHARM.NS)
The Valens Company Inc. (VLNS.TO)
Bliss GVS Pharma Limited (BLISSGVS.BO)
Ildong Holdings Co., Ltd. (000230.KS)
Ironwood Pharmaceuticals, Inc. (IRWD)
Fertil-A-Chron, Inc. (FEKR)
Business
Xiamen Kingdomway Group Company, founded in 1997 and headquartered in Xiamen, China, operates primarily in the pharmaceutical and biotechnology sectors specializing in nutritional and pharmaceutical raw materials. Its core product portfolio includes coenzyme Q10, DHA, ARA, vitamin A, vitamin D3, vitamin K2, nattokinase, PQQ, NMN, astaxanthin, and pharmaceutical raw materials such as praziquantel, alanyl glutamine, and olacetam. The company is one of the world's top manufacturers of vitamin A and vitamin D3, supplying products internationally and operating state-of-the-art manufacturing facilities certified to GMP and ISO standards. Recent major developments include the strategic acquisition of Viactiv, a US-based nutritional supplements firm, for $17.2 million in 2024, marking Kingdomway's significant expansion into the international over-the-counter (OTC) health product market. The company also reported robust financial performance in 2024, with revenue reaching approximately RMB 3.24 billion, a year-on-year increase of 4.43%, driven by growth in its vitamin and nutritional product segments. Additionally, Xiamen Kingdomway continues to invest heavily in research and development, with a focus on expanding its pipeline of biopharmaceutical products and enhancing manufacturing capabilities while emphasizing sustainability goals and international market expansion. Xiamen Kingdomway serves global markets with a strong presence in North America, Europe, and Asia, targeting pharmaceutical companies, health product distributors, and consumers seeking high-quality nutritional supplements and pharmaceutical ingredients. The company maintains a commitment to innovation and quality assurance as essential pillars for its business growth and competitive positioning.